KURA Company Profile and Key Details

Q: Who are the executives of KURA?

Ms. Kirsten FlowersChief Commercial Officer & Chief Corporation Strategy OfficerMr. Pete De SpainSenior Vice President of Investor Relations & Corporation CommunicationsDr. Stephen Dale M.D.Chief Medical OfficerMs. Kathleen FordChief Operating OfficerMr. Thomas DoyleSenior Vice President of Fin. & AccountingDr. Roger Bakale Ph.D.Vice President and Head of CMC, Clinical & Commercial ManufacturingMr. James E. Basta J.D., Esq.Chief Compliance Officer & Corporation Sec.Ms. Teresa Brophy Bair Esq., J.D.Chief Legal Officer & Corporation Sec.Ms. Maureen Clancy M.B.A.Vice President and Global Head of Program Leadership & Project ManagementDr. Troy Edward Wilson J.D., Ph.D.Co-Founder & Chairman

NASDAQ : KURA

Kura Oncology

$9.14

0.42+4.82%

At Close 4:00 PM

58.08

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Kura Oncology, Inc. (KURA) stock declined over -0.98%, trading at $9.05 on NASDAQ, down from the previous close of $9.14. The stock opened at $9.23, fluctuating between $8.90 and $9.28 in the recent session.

Stock Snapshot

9.14

Prev. Close

799.38M

Market Cap

8.895

Day Low

-2.85

P/E Ratio

-3.18

EPS (TTM)

-1.62

Cash Flow per Share

9.23

Open

88.33M

Number of Shares

9.279

Day High

96.92%

Free Float in %

5.14

Book Value

839.24K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Apr 14, 2026	9.02	9.23	8.91	9.14	1.69M
Apr 13, 2026	8.70	8.97	8.64	8.72	800.53K
Apr 10, 2026	8.81	8.84	8.58	8.67	879.49K
Apr 09, 2026	8.76	8.90	8.64	8.85	753.47K
Apr 08, 2026	9.04	9.10	8.66	8.79	1.05M
Apr 07, 2026	8.47	8.93	8.25	8.82	1.45M
Apr 06, 2026	8.61	8.80	8.46	8.49	837.94K
Apr 02, 2026	8.15	8.94	8.15	8.61	4.39M
Apr 01, 2026	8.11	8.56	8.09	8.34	1.36M
Mar 31, 2026	7.94	8.30	7.93	8.13	1.39M
Mar 30, 2026	7.71	7.79	7.54	7.73	1.2M
Mar 27, 2026	8.32	8.39	7.73	7.74	2.19M
Mar 25, 2026	8.36	8.63	8.26	8.55	1.01M
Mar 24, 2026	8.23	8.29	7.96	8.07	982.15K
Mar 23, 2026	8.39	8.50	8.05	8.32	1.42M
Mar 20, 2026	8.43	8.60	8.17	8.26	2.67M
Mar 19, 2026	8.31	8.52	8.17	8.43	779.24K
Mar 18, 2026	8.52	8.57	8.27	8.39	915.46K
Mar 17, 2026	8.80	8.82	8.56	8.58	784.83K
Mar 16, 2026	8.67	8.81	8.57	8.73	982.35K

Contact Details

San Diego, CA 92130

United States

https://kuraoncology.com 858 500 8800

About Company

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.

Stock Peers

ARGX

19.08+2.36%

argenx SE$828.35 REGN

9.05+1.21%

Regeneron Pharmaceuticals, Inc.$755.51 UTHR

0.91+0.16%

United Therapeutics Corporation$578.54 MDGL

-0.68-0.13%

Madrigal Pharmaceuticals, Inc.$524.99 VRTX

4.23+0.96%

Vertex Pharmaceuticals Incorporated$444.28 PRAX

26.6+8.39%

Praxis Precision Medicines, Inc.$343.60 ALNY

6.41+1.92%

Alnylam Pharmaceuticals, Inc.$339.41 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 KRYS

2.59+0.97%

Krystal Biotech, Inc.$270.00 ASND

1.29+0.52%

Ascendis Pharma A/S$249.84

Company Overview

Kura Oncology, Inc. (NASDAQ:KURA) closed at $9.05 USD, losing -$0.09 (-0.98%) from the previous close of $9.14. The stock is currently mid-range between its 52-week high and low $5.45 and $12.49. With a market capitalization of about $799.38 million, Kura Oncology, Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~0.24). Key stats such as the average daily volume over the past year has been around 1.45 million shares, volume is running light vs its 52-week average. Headquartered in San Diego, CA, Kura Oncology, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Troy Edward Wilson, the company employs approximately 192 people and listed since September 16, 2015. Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States.

Technical Performance

KURA has shown weak momentum, losing -6.22% over the past week and -12.6% over the past quarter, though year-to-date performance is down -17.23%. Short-term trend indicators are mixed aligned (SMA20 5.57%, SMA50 -4.59%, SMA200 4.0%). The stock’s 14-day RSI is 52.72 (neutral), while the ATR of 0.39 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -30.74% below its high and over 59.89% above its low. Average 10-day trading volume of 1.07 million shares is below the 3-month average of 1.43 million, indicating normal recent market interest.

Valuation Metrics

Kura Oncology, Inc. trades at a P/E ratio of -2.9, slightly below the S&P 500 average, with a price-to-sales ratio of 12.02 and a price-to-book ratio of 4.64 trading at moderately above to book value. The P/FCF stands at -11.48, also below market averages.

Dividend & Fair Value

Kura Oncology, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $19.54. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Kura Oncology, Inc. generated EPS of -$2.48 over the past year. Five-year average earnings growth is -6.05%. Wall Street analysts project EPS growth of -6.31% annually over the next five years. The latest quarter delivered EPS of -$0.85. The next quarter is forecast at -$0.64. Next year's EPS is expected at -$8.47. Analyst sentiment is bullish. Analyst rating data shows there are 8 Strong Buy ratings, 6 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $40.00 to $15.00. The high target offers 337.64% upside. The low target suggests 64.11% downside. The mean target is $29.79. This offers 225.93% upside. Kura Oncology, Inc. earnings surprise history is a mixed track record. The quarter that ended November 04, 2025, missed forecasts by 48.36%. The prior quarter beat by -600.0%. Over the last six quarters, Apple has recorded several small beats. These include -6.35% in August 08, 2024.

Shareholding & Insider Activity

Kura Oncology, Inc. has 86.80 million shares outstanding. The public float is 63.99 million shares, elevated short interest at 9.13% of float. This equals 7.91 million shares. The short ratio is 6.05 days. Institutional investors hold 97.04% of the float. Insiders own 1.2%. EcoR1 Capital Fund Qualified, L.P. holds 4.41 million shares, GUALBERTO ANTONIO has 339.97 thousand shares and Leoni Mollie has 267.27 thousand shares. Over the past six months, insider transactions show net selling. They sold 90.04 thousand shares across 13 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Kura Oncology has not generated any revenue. Returns are negative, with ROA at -34.00% and ROE at -38.42%.
On valuation metrics, Kura Oncology trades at a P/E of -2.90, P/S of 12.02 and P/B of 4.64. The current ratio is 6.06 and quick ratio is 6.05. Operationally, the company’s inventory turnover is 8.89 and cash conversion cycle is -389.47 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.12, supported by a cash flow-to-debt ratio of -3.13.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Kura Oncology posted revenue of $0.00, down slightly from $0.00 in the prior quarter. Gross profit was - $849.00K (margin 0.00%). Operating income was - $165.80M (margin 0.0%). Net income was- $152.63M (EPS - $2.08).
The company ended the quarter with $423.96M in cash and short-term investments, a total debt of $17.20M, and net debt of - $20.12M. Total assets were $448.94M, with equity of $397.27M. Financials further reflected weakness, with operating cash flow of - $124.82M, free cash flow of - $124.99M, and capital expenditures of - $168.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that Kura Oncology, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -2.63%, with price expected at $8.90 by April 28, 2026, within a range of $8.45 to $9.33 3-Month Outlook: Projected fall of -1.42%, reaching $9.01 by July 13, 2026, with a range of $8.44 to $9.45. 1-Year Outlook: Projected gain of 147.92%, with price at $22.66 by April 14, 2027, within a range of $7.99 to $35.84.

Key Takeaways

Kura Oncology, Inc. (NASDAQ:KURA) shares are down -17.23% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Kura Oncology, Inc. trading at a premium to the broader market with a P/E of -2.9. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $29.94, suggesting 227.57% upside. Our AI forecast model points to short-term weakness (-2.63% over two weeks), a medium-term fall (-1.42% over three months), and a longer-term gain (147.92% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Kura Oncology, Inc. (KURA) stock price?

Kura Oncology, Inc. (NASDAQ: KURA) stock price is $9.05 in the last trading session. During the trading session, KURA stock reached the peak price of $9.28 while $8.90 was the lowest point it dropped to. The percentage change in KURA stock occurred in the recent session was -0.98% while the dollar amount for the price change in KURA stock was - $0.09.

KURA's industry and sector of operation?

The NASDAQ listed KURA is part of Biotechnology industry that operates in the broader Healthcare sector. Kura Oncology, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of KURA?

Ms. Kirsten Flowers
Chief Commercial Officer & Chief Corporation Strategy Officer
Mr. Pete De Spain
Senior Vice President of Investor Relations & Corporation Communications
Dr. Stephen Dale M.D.
Chief Medical Officer
Ms. Kathleen Ford
Chief Operating Officer
Mr. Thomas Doyle
Senior Vice President of Fin. & Accounting
Dr. Roger Bakale Ph.D.
Vice President and Head of CMC, Clinical & Commercial Manufacturing
Mr. James E. Basta J.D., Esq.
Chief Compliance Officer & Corporation Sec.
Ms. Teresa Brophy Bair Esq., J.D.
Chief Legal Officer & Corporation Sec.
Ms. Maureen Clancy M.B.A.
Vice President and Global Head of Program Leadership & Project Management
Dr. Troy Edward Wilson J.D., Ph.D.
Co-Founder & Chairman

How KURA did perform over past 52-week?

KURA's closing price is 67.71% higher than its 52-week low of $5.45 where as its distance from 52-week high of $12.49 is -26.82%.

How many employees does KURA have?

Number of KURA employees currently stands at 192.

Link for KURA official website?

Official Website of KURA is: https://kuraoncology.com

How do I contact KURA?

KURA could be contacted at phone 858 500 8800 and can also be accessed through its website. KURA operates from 12730 High Bluff Drive, San Diego, CA 92130, United States.

How many shares of KURA are traded daily?

KURA stock volume for the day was 839.24K shares. The average number of KURA shares traded daily for last 3 months was 1.45M.

What is the market cap of KURA currently?

The market value of KURA currently stands at $799.38M with its latest stock price at $9.05 and 88.33M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	192
Beta	0.24
Sales or Revenue	$0.00
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

KURA Company Profile and Key Details

Kura Oncology

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Dividend & Fair Value

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Company Overview

Valuation Metrics

Key Takeaways

Price Forecast & Outlook